Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)

Table 2 The predicted T cytotoxic cells epitopes, their antigenicity, allergenicity, toxicity and the population coverage from spike S protein and orf1ab polyprotein

Protein	Epitopes	Start	End	Vaxijen antigenicity (0.4)	Allergenicity	Toxicity	Population coverage
Spike S protein	FTISVTTEI	718	726	0.8535	Nonallergen	Nontoxin	52.54%
	FVFLVLLPL	2	10	0.8601	Nonallergen	Nontoxin	48.45%
	VVFLHVTYV	1060	1068	1.5122	Nonallergen	Nontoxin	48.45%
	VRFPNITNL	327	335	1.1141	Nonallergen	Nontoxin	41.68%
	^aFAMQMAYRF	898	906	1.0278	Nonallergen	Nontoxin	39.96%
orf1ab	^aVMYASAVVL	3683	3691	0.4778	Nonallergen	Nontoxin	57.06%
	SLIYSTAAL	2242	2250	0.452	Nonallergen	Nontoxin	51.80%
	MMISAGFSL	6425	6433	1.0248	Nonallergen	Nontoxin	51.47%
	FVMMSAPPA	1804	1812	0.4871	Nonallergen	Nontoxin	48.97%
	FLLNKEMYL	3183	3191	0.44	Nonallergen	Nontoxin	45.42%
	^aFLLPSLATV	3639	3647	0.5954	Nonallergen	Nontoxin	40.60%
	^aSLENVAFNV	6453	6461	1.0488	Nonallergen	Nontoxin	40.60%

^athe overlapped epitopes between MHCI and MHCII molecules were used once in the vaccine construct as MHCI or MHCII epitopes

ISSN: 1471-2172